knowledge -WSS

knowledge

author：knowledge 2025-10-02 00:42:53 - browse：73468

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Stroke rates rising, especially in working

focus

WSS

Study suggests Covid rebound is far more common with Paxlovid than without

Congress: Prevent baby formula shortages by passing a new bill

Carbon Health diabetes program, a test of data

Ventyx halts psoriasis drug development after lackluster trial results

Decentralized clinical trials need collaboration to achieve wider use

CVS, Rite Aid closures threaten to worsen pharmacy deserts

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

Activists slam private health insurers over coverage restrictions

Weight loss drugs should be covered by insurers, AMA says

Anesthesiologist group: stop taking Ozempic before surgery

What is STAT's opinion section for?

Malaria cases in Florida and Texas: Here’s what you need to know

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Affirmative action in medical school literally saved lives

Achieving telehealth equity for people with hearing loss

Sports medicine is finally prioritizing gender equality

The Bio Revolution is changing business and society

knowledge

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Medicare’s new pay boost for primary care is angering specialists

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Carbon Health diabetes program, a test of data

UnitedHealth sued over use of algorithm in Medicare Advantage plans

focus

explore

leisure time

explore